Description

Global Gene Editing Market Outline

 

Gene editing or Genome editing is the type of genetic editing where DNA is inserted, replaced or deleted in the genome of an organism in order to treat a specific disease by using a molecular scissors or engineered nuclease. These nucleases create site-specific double-stranded breaks in desired locations in genome. The induced double-stranded breaks are repaired through nonhomologous end joining or homologous recombination resulting in targeted mutations (edits).

 

Rise in the prevalence rate of cancer & other genetic disorders, increasing preference in the  personalized medicine, companies investments towards R&D, and growth of biotechnology and pharmaceutical industries, increase in private and public sector funding, rapid advancements in sequencing and gene editing technologies, applications in various drug discovery processes are some of the factors propelling the growth of the gene editing market. However, global gene editing market is hindered by stringent government regulations to approve gene mutation projects, ethical issues, unavailability of gene editing based therapeutics in the market and lack of awareness among people regarding the safety of genetic interventions.

 

SCOPE OF GLOBAL GENE EDITING MARKET

 

Gene Editing Market

Gene Editing Market

 

On the basis of technology, Global Market is segmented as:

  • Zinc Finger Nuclease (ZFN)
  • Clustered regularly interspaced short palindromic repeats (CRISPR)
  • Transcription activator-like effector nuclease (TALEN)
  • Others

 

On the basis of application, Global Market is segmented as:

  • Cell Line Editing
  • Targeted gene mutation
  • Animal Genome Editing
  • Plant Genome Editing

 

On the basis of product type, Global Market is segmented as:

  • Consumables
  • Instruments and Software

 

On the basis of end-user, Global Market is segmented as:

  • Pharmaceutical companies
  • Biotechnology Companies
  • Academics
  • Clinical Research Organizations

 

Biotechnology and pharmaceutical sectors dominate gene editing market due to its applications in drug discovery and therapeutics. Rise in usage of CRISPR and ZFN, companies are investing in innovative research for development of novel gene editing techniques. Many players are adopting various strategies which include collaborations for R&D outsourcing, mergers and acquisitions, strategic or manufacturing activities are driving the growth of gene editing market. For instance, in 2014, Thermo Fisher acquired Life technologies, to create unbeatable leadership in life sciences, research, speciality diagnostics and applied markets.In 2014, Sigma-Aldrich Corporation (U.S.) entered into an agreement with Broad Institute of MIT and Harvard (U.S.) to use CRISPR technology. High growth potential in emerging regions provides lucrative opportunities to industry players.

 

On the basis of Geographical regions, the gene editing market categorized into five regions:, Europe, North America, Latin America, Asia Pacific, and Middle East & Africa. The gene editing market is dominated by North America due to the strong growth trend in the pharmaceuticals and biotechnology industries. Emerging economies of Asia Pacific and Latin America are expected to show significant growth in the gene editing market due to an increase in the number of laboratories in these regions and development of existing ones for automation of various instrumentation systems, the expansion of leading gene editing companies and increased R&D spending.

 

Some of the players in Global market are Cellectis S.A. (France), Applied Stemcell, Inc. (U.S.),  Genscript (U.S.), Merck KGaA (Germany), Horizon Discovery Group plc,(U.K.), Origene Technologies, Inc. (U.S.), System Biosciences, Inc. (U.S.), Sangamo Therapeutics, Inc.(U.S.), Thermo Fisher Scientific (U.S), and Transposagen Biopharmaceuticals, Inc.(U.S.)

 

  • In July 2017, Cellectiswas granted the European Patent for the invention of the genetically engineering T-cells by adopting RNA-guided endonucleases, such as CRISPR associated protein 9 (Cas9) or Centromere and Promoter Factor 1(Cpf1 )

 

  • In July 2017 Sangamo Therapeutics, Inc. received the U.S.FDA Fast Track designation for in vivo gene editing product candidates SB-318 and SB-913 to treat Mucopolysaccharidosis Type I (MPS I) and MPS II

 

  • In November 2016, OriGene Technologies entered strategic agreement with EdiGene (Beijing, China) for the development of gene-wide knockout cells from laboratory cell lines which are commonly used

 

Global Gene Editing Market Report Outline:

 

  • The report provides granular level information about the market size, regional market share and forecast from 2017-2024
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario


Location

GEOGRAPHY

PBI Location Map

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX